Iovance Biotherapeutics, Inc.
NASDAQ:IOVABiotechnology
-$0.04 today
- Market cap
- $3.46B
- Beta
- 0.70
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.85
Volume 6.99M
Average 14.09M
IOVA Total Debt
Short-term and long-term borrowings combined.
Iovance Biotherapeutics, Inc.NASDAQ: IOVA
Total Debt · Q3 FY2026 · quarter ended Sep 2026
Total debt falls 13.9% from a year ago
Total debt stood at $45.21M at the end of Q3 FY2026, down 13.9% from a year earlier and down 1.7% from the prior quarter. Over 3 fiscal years it compounded at -17.2% a year.
Context
- Total debt amounted to 4.6% of total assets at the end of Q3 FY2026, down 1.2 pp from a year earlier.
- Total debt increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -13.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 48.44M USD
- Year-over-year change
- -16.9%
- 4-year CAGR
- -9.3%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 48.44M | -16.9% |
| FY2024 | 2024-12-31 | 58.26M | -23.2% |
| FY2023 | 2023-12-31 | 75.86M | -11.2% |
| FY2022 | 2022-12-31 | 85.45M | +19.5% |
| FY2021 | 2021-12-31 | 71.53M | — |
Total Debt vs competitors
How IOVA compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -13.9% is the 9th highest of 11, against a peer median of +0.4%.
- Total debt amounts to 4.6% of total assets for IOVA, versus a peer median of 16.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $5.27B USD | +3463.6% | +108.7% | 42.1% | |
| Sep 2026 | $869.52M USD | +60.4% | +6.7% | 142.7% | |
| Mar 2026 | $435.68M USD | +0.4% | +75.0% | 40.6% | |
| Jun 2026 | €315.97M EUR | +17.2% | +8.0% | 1.6% | |
| Sep 2026 | $167.4M USD | -59.2% | +13.3% | 10.0% | |
| Mar 2026 | $76.79M USD | -7.9% | -10.7% | 27.0% | |
| Dec 2025 | $76.35M USD | +0.4% | +32.4% | 22.9% | |
| Sep 2026 | $45.21M USD | -13.9% | -17.2% | 4.6% | |
| Sep 2026 | $10.26M USD | +155.6% | +136.6% | 2.0% | |
| Mar 2026 | $5.22M USD | -47.7% | -20.6% | 2.9% | |
| Mar 2026 | $2.89M USD | -9.5% | -21.0% | 2.8% | |
| Peer median (excluding IOVA) | — | +0.4% | +10.6% | 16.4% | |
Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 78.23M | 231.73M | 114.89M | 115.69M | 163.08M |
| Short-term Investments | 426.18M | 240.11M | 164.98M | 208.09M | 133.9M |
| Net Receivables | 0 | 0 | 151K | 69.34M | 82.45M |
| Inventory | 0 | 0 | 10.37M | 51.52M | 51.68M |
| Other Current Assets | 0 | 7.27M | 17.46M | 12.38M | 11.58M |
| Total Current Assets | 507.96M | 479.12M | 307.85M | 457.02M | 442.69M |
| Property, Plant & Equipment (Net) | 169.92M | 178.25M | 176.55M | 164.28M | 177.01M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 229.26M | 282.4M | 279.32M |
| Long-term Investments | 91.59M | 0 | 66.43M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 7.87M | 6.62M | 270K | 6.73M | 14.15M |
| Total Non-current Assets | 269.38M | 184.87M | 472.5M | 453.41M | 470.48M |
| Total Assets | 777.33M | 663.98M | 780.35M | 910.43M | 913.17M |
| Account Payables | 27.38M | 26.6M | 33.12M | 27.51M | 22.16M |
| Short-term Debt | 0 | 0 | 0 | 0 | 4.04M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 34.59M | 50.03M | 112.16M |
| Total Current Liabilities | 89.2M | 91.49M | 110.31M | 122.34M | 138.36M |
| Long-term Debt | 1M | 1M | 1M | 1M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 17.35M | 32.32M | 31.83M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 66.47M | 72.86M | 85.43M | 77.68M | 76.23M |
| Total Liabilities | 155.67M | 164.34M | 195.74M | 200.02M | 214.59M |
| Common Stock | 7K | 8K | 11K | 13K | 17K |
| Retained Earnings | (1.17B) | (1.57B) | (2.01B) | (2.38B) | (2.78B) |
| Accumulated OCI | (601K) | (902K) | 2.53M | (1.05M) | 16.44M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 621.66M | 499.64M | 584.61M | 710.41M | 698.58M |
| Total Debt | 71.53M | 85.45M | 75.86M | 58.26M | 48.44M |
| Net Debt | (6.7M) | (146.29M) | (39.03M) | (57.43M) | (114.63M) |
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
Intrinsic Alpha fair value
Locked
Current Price
$7.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.